Cargando…
Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update
SIMPLE SUMMARY: Only 5% of all drug-related targets currently move from preclinical to clinical in cancer, and just some of them achieve patient’s bedside. Among others, intratumor heterogeneity and preclinical cancer model limitations actually represent the main reasons for this failure. Cyclic-AMP...
Autores principales: | Sapio, Luigi, Salzillo, Alessia, Ragone, Angela, Illiano, Michela, Spina, Annamaria, Naviglio, Silvio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693618/ https://www.ncbi.nlm.nih.gov/pubmed/33126560 http://dx.doi.org/10.3390/cancers12113166 |
Ejemplares similares
-
The KDM Inhibitor GSKJ4 Triggers CREB Downregulation via a Protein Kinase A and Proteasome-Dependent Mechanism in Human Acute Myeloid Leukemia Cells
por: Illiano, Michela, et al.
Publicado: (2020) -
Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells
por: Salzillo, Alessia, et al.
Publicado: (2021) -
Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines
por: Ragone, Angela, et al.
Publicado: (2022) -
AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance?
por: Sapio, Luigi, et al.
Publicado: (2022) -
AdipoRon Affects Cell Cycle Progression and Inhibits Proliferation in Human Osteosarcoma Cells
por: Sapio, Luigi, et al.
Publicado: (2020)